Hair Restoration Market Size Worth $13.6 Billion By 2028 | CAGR: 15.4%: Grand View Research, Inc. – PRNewswire

SAN FRANCISCO, March 31, 2021 /PRNewswire/ -- The global hair restoration marketsize is anticipated to reach USD 13.6 billion by 2028, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 15.4% from 2021 to2028. Hair restoration technique which includes surgical as well as a non-invasive treatment option is an effective procedure to increase hair thickness, fill in a receding hairline, and treat baldness as well as severe alopecia. According to the American Academy of Dermatology, androgenic alopecia is the most common cause of hair loss in both men and women. According to the American Hair Loss Association, 95 % of hair loss in men is caused by androgenetic alopecia and around 40% of men notice symptoms of baldness by the age of 40.

Key suggestions from the report:

Read 107 page research report with ToC on "Hair Restoration Market Size, Share & Trends Analysis Report By Procedure (Follicular Unit Extraction, Follicular Unit Transplantation), By Therapy (Low-level Laser Therapy, Stem Cell Hair Restoration, Platelet-rich Plasma), And Segment Forecasts, 2021 - 2028" at : https://www.grandviewresearch.com/industry-analysis/hair-restoration-market

The market is currently witnessing a surge in treatment adoption due to high psychological stress, poor dietary habits, reduced nutritional levels with age progression, and increasing hormonal changes due to lifestyle shifts among the global population. This surge can also be due to the increased success rate of the transplantation procedures and technological advancement in the field of less invasive hair repair.

In the light of COVID-19, the market was hampered as the footfall of patient appointments for surgical Follicular Unit Extraction (FUE) or Follicular Unit Transplantation (FUT) treatments was temporarily suspended. However since the government in many countries has allowed resuming elective surgical procedures, clinics have also started hair transplant procedures again and international organizations like the International Society of Hair Restoration Surgery (ISHRS) has set strict protocols for resuming hair restoration practices as well as offer patient guidance in finding hair repair clinics deemed.

Grand View Research has segmented the global hair restoration market on the basis of procedure, therapy, and region:

List of Key Players of Hair Restoration Market

Find more research reports on Medical Devices Industry,by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: [emailprotected] Web: https://www.grandviewresearch.com Follow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

View post:
Hair Restoration Market Size Worth $13.6 Billion By 2028 | CAGR: 15.4%: Grand View Research, Inc. - PRNewswire

How Aviv Clinics in Florida’s The Villages Retirement Community Fights Aging – menshealth.com

Its 5:30 p.m. on a Tuesday, and happy hour has begun at Brownwood Paddock Square inside the Villages, a 55-plus active--retirement community in Florida. Gray-haired couples amble along the sidewalks of the early-1800s-western-themed town center, toting folding chairs and cooler s. A band is playing Blue Suede Shoes in the corral. Maskless throngs in windbreakers and visors shuffle out of the restaurants and bars, scoping out the best spots for the concert. Customized golf cartsfuchsia, blaze orangeline the curb, glimmering in the light of the setting sun.

In the past, I would have smiled condescendingly at this scene. (Aw, look at these oldsters rocking out on their new knees!) Instead, I drink it in, pondering my own mortality. Im 55officially old enough to live at the Villagesand am here to visit the new Aviv Clinics, which offers a compelling and potentially game-changing therapy to combat the effects of aging.

Rhona Wise/AFP via Getty Images

The Villages is a location, but its also a concept: a place where the almost old, and the actually old, go to feel less old. Its where you can act young without being young, and its where an estimated 132,000 people (and countingthe metro area has one of the fastest growth rates in the country) are testing the hypothesis that feeling young is more a mindset than a number. There are 50 golf courses and more than 3,000 clubs and activities, from karate to knitting. It may seem counterintuitive, but this city/club/social experiment may offer a glimpse of the future. Your future, specifically.

Americans are an aging population for the obvious reasons. Medical breakthroughs mean more of us live longer, and the surge of baby boomers born after World War II are hitting their senior years. By 2030, one in five adults will be at least 65, according to the U.S. Census Bureau. With the power of numbers, this 65-plus crowd is changing how we think about growing old, challenging the convention that seniors should rest and take things easy.

EVE EDELHEIT/The New York Times/Redux

People often compare the Villages to Disney World, given the themed town centers. But Glenn Colarossi, the head of Avivs business development and my host, likens it to a college campus for the retired. They like to have fun, he observes. The Villages is reimagining our notion of the golden years, and Aviv is greasing the wheelsand jointsof this revolution. Its goal, Colarossi tells me, is to increase a persons health span, not just their life span.

Men's Health

Pioneered by Israeli physician Shai Efrati, M.D., the clinic studies each client down to their DNA and constructs a personalized plan for staying physically and mentally healthy. The centerpiece is hyperbaric oxygen therapy (HBOT), in which patients breathe pure oxygen at varying pressures in a hyperbaric chamber, potentially inducing cell growth and expanding blood vessels in the brain. The original research center in Israel opened 15 years ago, and the Florida site opened in March 2020. If I were entering the 12-week program, Id meet with a physical therapist, a physiologist, a doctor, and a dietitian; engage with millions of dollars worth of machinery; and submit DNA, which would result in a 200-page book of codes and genetic indicators that each of the experts would parse. There would be 60 sessions in the hyperbaric chamber as well as before-and-after MRI and SPECT brain scans. The program cost: $45,000. Is this just another get-young-quick fad for the rich and yet another reminder of our health-care systems inequalities? Or do HBOT and a customized evaluation of your physiology offer some chance to counteract declining brain and body function and help in the fight we all eventually fightthe one against aging?

Bob Croslin

The Aviv lobby where I check in is a cavernous expanse of white tile and polished wood. The overhead lights double as sculptures. It is celestially sleek. If the designers were going for a Gods-waiting-room vibe, they nailed it. Im scheduled for a sample of the three-day assessment, condensed into two days. I dont feel or even think of myself as old. I run regularly with my wife and take boxing classes with my oldest. The other day, when I barked at my teenage daughter to get off the phone and do the dishes, she muttered, Grumpy old man. We locked eyes...and laughed. Funny because it was so not true. But I do have persistent lower-back pain, and odds are 50-50 I get up in the middle of the night to pee. Then theres the looming shadow of declining brain function, which for someone who lost his father to Alzheimers is too terrifying to joke about.

My first evaluation will determine my physical and cardiopulmonary state. I meet with Ankita Shukla, D.P.T., a trim, sharp woman who runs me through a gauntlet of tests to measure the flexion, extension, rotation, and abduction of every joint in my body, zeroing in on the limited range of motion in my neck and back...and (sigh) knees, wrists, and hips.

Bob Croslin

In one test, to assess my dual-task ability, she asks me to briskly walk to a cone while counting down from 100, subtracting each number by three. I utter only two numbers, one of which is right. On my second attempt, I actually count forward, not backward. She recommends a serious stretching regimen for my body, neck, hips, and wrists. For posture, she offers a quick cheat: stand with my back against a wall for more than a minute at intervals throughout the day. To increase my dual tasking, she suggests I count backwardnumbers, months, the alphabetduring my workouts.

Shukla hands me off to physiologist Aaron Tribby, a fit young man who is a body-movement specialist. Tribby straps me into the Gaitway 3D, a biomechanics treadmill that measures my gait and step pressure to check my coordination and see if Im losing functionality. I have some foot rotation, which might be caused by tight hip flexors, taut hamstrings, or rigid ankles. He gives me exercises to remedy all three.

Bob Croslin

Next, I visit Roger Miller, Ph.D., Avivs charming clinical psychologist. Ive got the best job here, because everything is controlled by the brain, he proclaims with a smile. Im going to tell you five words, he instructs. I want you to repeat them to me. I ace it. Then I take a battery of increasingly difficult cognitive tests: the written Montreal Cognitive Assessment, or MoCA (at the end of this test, he asks me to recite the five words again; I dont ace it); the NeuroTrax, to assess functions like memory, attention, and problem-solving; the CANTAB, which looks at processing speed, flexible thinking, and spatial memory. The results: You showed comparative strengths in your nonverbal memory, fine motor speed and coordination, and executive-function skills. And in a sentence ripped right from my wifes playbook: There were relative weaknesses in your information-processing speed and sustained attention.

None of the testing so far is super cutting-edge, and the advice, while sound, is mostly stuff I knew I should be doing. I then meet with Mohammed Elamir, M.D., the lead physician at Aviv who runs point on interpreting all the data from the team, including from specialized brain scans that track blood flow in the brain and identify diminished zones, to gain a holistic view of how a patient is aging. I didnt get the brain scans, so Dr. Elamir gives me a basic neuroscience history lesson, which like everything else at Aviv traces back to its cofounder Dr. Efrati. Dr. Elamir tells me he was drawn to Aviv because he came across research by Dr. Efrati that indicated that central-nervous--system cells in the brain could regenerate and rejuvenate. That is not what we were taught in medical school, he says. This was not deemed feasible. Now, he says, thanks to Dr. Efratis HBOT research, there is preliminary evidence they can.

Bob Croslin

Dr. Efrati is a professor at the Sackler School of Medicine at Tel Aviv University and the founder and director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center. He has been studying the effects of hyperbaric oxygen therapy for more than 20 years, he tells me on a Zoom call. Hes 50, with close-cropped gray hair and a warm, TED-talk-polished bedside manner. Dr. Efrati says he developed an interest when a stroke patient with an ulcerated leg wound was put in a hyperbaric chamberan accepted wound therapy. After a series of treatments, he noticed the womans neurological disabilities were improving as well. This led him to investigate the regenerative effects of HBOT on the brain. He discovered in 2007 that, indeed, neurons and blood vessels in the brain can be regenerated.

The apotheosis of his work was identifying a phenomenon called the hyperoxic--hypoxic paradox. By manipulating levels of oxygen in the chamber, you can essentially fool the body into perceiving that its being starved of oxygen, a state called hypoxia, without harmful side effects. During the hyperoxic stage, oxygen floods the cells. According to Dr. Efrati, this can promote the production of stem cells, valuable because they can develop into most any cell in the body. The treatment can also promote the branching of new blood vessels into areas of the brain damaged by events like strokes.

Bob Croslin

Dr. Efrati started treating stroke patients with HBOT in 2007, then brain--trauma patients in 2008. Today, he works with people who want to remain physically and mentally active. About five years ago, we decide we move forward with targeting aging as a disease, he says.

Dr. Efratis recent research results are intriguing. Notably, a November 2020 clinical trial of 35 people ages 64 and older indicates that HBOT can increase the length of telomeres, the area of specialized protein at the ends of chromosomes. (Telomere shortening is a sign of aging.) Another of his clinical trials published last June, of 63 patients, found evidence of cognitive enhancement in adults ages 64 and older after HBOT. The specific benefits were increased cerebral blood flow resulting in improvement in executive function, information--processing speed, and attention.

However, there is skepticism in the wider medical community. Usually, small clinical studies would be followed by larger, multicenter, randomized clinical trials, says James E. Galvin, M.D., M.P.H., a professor of neurology and the director of the Comprehensive Center for Brain Health at the University of Miami. This has not happened with HBOT yet. Dr. Galvin, who is engaged in dementia--prevention-and-therapy research, is familiar with Dr. Efratis work. I think one should be cautious about overinterpreting results from very small studies performed at single sites with very small effects, he says. Im not discounting the research. Theres just not a lot of research on HBOT use in patients with various forms of dementia. He adds that the majority of studies appear to be on only one type of dementia: vascular. Im cautious about rushing treatments for broad commercial use before the research shows its effective.

Bob Croslin

Even though HBOT therapy is new, I see about 20 other patients during my visit, mostly couples, in their 70s and 80s. (Aviv declined to reveal patient data.) Im reminded of something Dr. Elamir told me: The motivation for treatment he hears most from patients is not wanting to be a burden on their partner when cognitive decline, dementia, or stroke makes them less independent. One patient I talk to, Elliot Sussman, M.D., is the chairman of the Villages Health health-care provider. Dr. Sussman, 69, is 45 diveswhat they call sessions in the hyperbaric chamberinto the program. Even though the preprogram MRI of his brain was normal, his goal, he says, is to sharpen his cognitive function. But the most notable effect for him has been a significant increased need for sleep, he says, an additional hour or more every night. This is good news, the doctors told him, a sign his brain is regenerating and repairing, in the same way babies need sleep to aid development of their growing brains. It may seem underwhelming, but Dr. Sussman feels the investment will pay off.

After a night observing the Villages frenetic social scene, Im up early the next morning to meet registered dietitian Kathryn Parker, a cheery woman with flowing gray hair. She has me stand on the Seca Medical Body Composition Analyzer and grip the handles. Within minutes, a report is compiled that assesses my water composition (good, at 58 percent), my visceral adipose tissue (fat around my organs, which is very good, at 1.9 on a chart that goes to 5), and a host of other things, including skeletal muscle mass (which at 63 pounds for my 167-pound body is okay; she wants it to be between 64 and 84). Im losing muscle mass as I age, and Ill need it to keep from falling down when Im actually old. She suggests I do more strength training and eat more protein daily. (MH advises eating about one gram of protein per pound of your target weight each day.) Parker likes nutrients to come from food (rather than supplements) and recommends snacks of yogurt, cheese, and whey-powder shakes. Its refreshingly straightforward nutrition advice.

Then Im back with physiologist Tribby for a spirometry and VO2-max stress test. He tapes on ten electrodes for the ECG, straps a mask over my head, and puts me on a treadmill. As both speed and incline gradually increase, Im instructed to run until I just cant go anymore, whatever that means. Nine minutes later, I find out. The ensuing report shows that my lung efficiency, including the amount of air I take in and forcibly exhale, is normal for my age and gender. At 34 kg/min, my max oxygen intake during intense exercise is a little better than average for my age. But before this goes to my head, Tribby points out that elite athletes test more than double that. My report is five pages of mediocrity, challenging my self-image as fit. To improve my fitness, he recommends standard stuff: exercise three or four days a week at 70 to 80 percent of my max heart rate, which is 165 bpm. I also need to work in a couple sessions of HIIT and one endurance workout.

Bob Croslin

Finally, Im ready for my dive. The chamber is designed like an airplanes first-class compartments to combat the claustrophobia some may feel and because it looks cool. I wear a mask to breathe the oxygen and sit in a very comfortable chair for an hour, half a regular session. The scheduled air and oxygen intervals at pressure induce the hyperoxic--hypoxic paradox. My breaths through the mask are slightly easier than breathing through a scuba regulator, but Im conscious of every inhale and draw the air deep into my lungs. My one session wont have a measurable effect on my brain, but I get the idea. When I emerge, Im light--headed. That night, I sleep deeply, my brain awash, presumably, in increased O2.

My two days give me only a glimpse inside the Aviv process. The data I get from my biometric measurements puts me in a good placeno immediate evidence that my body is aging faster than my brain, or vice versa, just that I am inexorably getting older. This one-stop mind-body checkup has taught me that (a) its great to have access to a team of medical experts under one roof and (b) I need to adhere to health and antiaging best practices, now more than ever. Physically Im inspired to do more stretching, improve my posture, up the exercise intensity, and eat more protein. I might even take up knitting to stay sharp. My exposure to the Villages has challenged me to look unflinchingly at the future and play and prepare for the long game.

More than anything, Im relieved there were no cognitive red flags. I couldnt afford the $45,000 price tag to potentially reverse a brain problem. Hopefully the science behind HBOT will be proved effective and the cost will come down. Until then, the prospect that age-related cognitive decline can be staved off gives me optimism that Ill stay active long enough to keep that smirk off my daughters face for decades to come.

This story appears in the May 2021 issue of Men's Health with the headline Where Aging Goes To Die.

Original post:
How Aviv Clinics in Florida's The Villages Retirement Community Fights Aging - menshealth.com

$16.89 Billion Nerve Repair and Regeneration Markets, 2026 – PRNewswire

DUBLIN, March 29, 2021 /PRNewswire/ -- The "Nerve Repair and Regeneration Market by Product, Application, End-User Geography - Global Opportunity Analysis and Industry Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

The Nerve Repair and Regeneration market is predicted to reach $16.89 Billion by 2026 from $8.62 Billion in 2020, at a CAGR of ~11.8% during the forecast period.

Nerves are collective neurons, which help in sending messages from one body part to another part like signals. Injuries can cause damage to nerve cells and may not be able to send signals to and from the brain. Nerve damage can cause due to the pressure, stretching, or cutting of a nerve. Nerve repair and regeneration process can help to restore the nerves to the normal condition.

Globally, major factors contributing to the Nerve repair and regeneration market growth include increasing number of nerve injuries, rapidly increasing old population where the nerves are very sensitive in this group as well as the rapidly growing neurological disorders. However, the lack of trained professionals and strict regulations are constraints in the market growth.

Based on product segment neurostimulation and neuromodulation devices segment accounted the largest share in the nerve repair and regeneration market due to the increasing occurrences of peripheral nerve injuries, advance technology in the nerve repair and regeneration, and the benefits of reimbursement policies are the factors enhancing the market growth.

Further, based on application neurostimulation and neuromodulation segment is expected to have the largest share in the market due to the rapidly increasing neurological disorders such as epilepsy, Alzheimer's disease, and other dementias and growing occurrences of peripheral nerve injuries.

The nerve repair and regeneration market, based on end-users the market is segmented into hospitals and clinics and ambulatory surgery centers. Hospitals segment accounted for the largest share in the market due to the increasing number of nerve repair and nerve surgery procedures in hospitals, increased old population, and well-established healthcare infrastructure.

On the bases of geography, the market is segmented into four regions includes North America, Europe, APAC, and RoW. North America is dominating the market growth due to the increased cases of nerve injuries, well-established healthcare centers in this region, and high investments in the healthcare industry in this region are factors solidifying the growth.

Globally, the nerve repair and regeneration market is expanding due to the increasing neurological disorders; emerging technologies in the field of neurological surgeries, increasing elderly population in all over the world are the factors driving the nerve repair and regeneration market. Emerging countries are expected to be the future markets and give a new opportunity for market growth. Somehow, difficulties may occur in treating the large nerve gaps, and this is the challenge for the market growth.

The key market players in the Nerve Repair and Regeneration market are Livanova, Orthomed, Axogen, Baxter, Integra Lifescience, Abbott Laboratories, Boston Scientific, Nevro, Stryker, Medtronic, Polyganics, and Neuropace.

Key Topics Covered:

1. Executive Summary

2. Industry Outlook 2.1. Industry Overview 2.2. Industry Trends

3. Market Snapshot 3.1. Market Definition 3.2. Market Outlook 3.3. PEST Analysis 3.4. Porter Five Forces 3.5. Related Markets

4. Market characteristics 4.1. Market Evolution 4.2. Market Trends and Impact 4.3. Advantages/Disadvantages of Market 4.4. Regulatory Impact 4.5. Market Offerings 4.6. Market Segmentation 4.7. Market Dynamics 4.8. DRO - Impact Analysis

5. Product: Market Size & Analysis 5.1. Overview 5.2. Neurostimulation and Neuromodulation Devices 5.2.1. Internal Neurostimulation Devices 5.2.1.1. Spinal Cord Stimulation 5.2.1.2. Deep Brain Stimulation 5.2.1.3. Vagus Nerve Stimulation 5.2.1.4. Sacral Nerve Stimulation 5.2.1.5. Gastric Electrical Stimulation 5.2.2. External Neurostimulation Devices 5.2.2.1. Transcutaneous Electrical Nerve Stimulation 5.2.2.2. Transcranial Magnetic Stimulation 5.3. Biomaterials 5.3.1. Nerve Conduits 5.3.2. Nerve Protectors 5.3.3. Nerve Wraps 5.3.4. Nerve Connectors

6. Application: Market Size & Analysis 6.1. Overview 6.2. Neurostimulation and Neuromodulation Surgeries 6.2.1. Internal 6.2.2. External 6.3. Direct Nerve Repair/Neurorrhaphy 6.3.1. Epineural Repair 6.3.2. Perineural Repair 6.3.3. Group Fascicular Repair 6.4. Nerve Grafting 6.4.1. Autografts 6.4.2. Allografts 6.4.3. Xenografts 6.5. Stem Cell Therapy

7. End User: Market Size & Analysis 7.1. Overview 7.2. Hospitals & Clinics 7.3. Ambulatory Surgery Centers

8. Geography: Market Size & Analysis 8.1. Overview 8.2. North America 8.3. Europe 8.4. Asia Pacific 8.5. Rest of the World

9. Competitive Landscape 9.1. Competitor Comparison Analysis 9.2. Market Developments 9.3. Mergers and Acquisitions, Legal, Awards, Partnerships 9.4. Product Launches and execution

10. Vendor Profiles 10.1. Axogen 10.2. Baxter 10.3. Boston Scientific 10.4. Livanova 10.5. Integra Lifesciences 10.6. Medtronic 10.7. Abbott Laboratories 10.8. Stryker 10.9. Polyganics 10.10. Nevro

11. Companies to Watch 11.1. Neuropace 11.2. Orthomed 11.3. Nevro

12. Analyst Opinion

For more information about this report visit https://www.researchandmarkets.com/r/g6v44i

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Continue reading here:
$16.89 Billion Nerve Repair and Regeneration Markets, 2026 - PRNewswire

Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News – FLA News

Stem cells are found in all human beings, from the initial stages of human growth to the end of life. All stem cells are beneficial for medical research; however, each of the different kinds of stem cells has both limitations and promise. Embryonic stem cells that can be obtained from a very initial stage in human development have the prospect to develop all of the cell types in the human body. Adult stem cells are found in definite tissues in fully developed humans. Stem cells are basic cells of all multicellular animals having the ability to differentiate into a wide range of adult cells. Totipotency and self-renewal are characteristics of stem cells. However, totipotency is seen in very early embryonic stem cells. The adult stem cells owes multipotency and difference flexibility which can be exploited for next generation therapeutic options. Recently, scientists have also recognized stem cells in the placenta and umbilical cord blood that can give rise to several types of blood cells. Research for stem cells is being undertaken with the expectation of achieving major medical inventions. Scientists are attempting to develop therapies that replace or rebuild spoiled cells with the tissues generated from stem cells and offer hope to people suffering from diabetes, cancer, spinal-cord injuries, cardiovascular disease, and many other disorders.

The stem cell therapy market is segmented on the basis of type, therapeutic applications, cell source, and geography. On the basis of type, the stem cell therapy market is categorized into allogeneic stem cell therapy and autologous stem cell therapy. Allogeneic stem cell therapy includes transferring the stem cells from a healthy person (the donor) to the patients body through high-intensity radiation or chemotherapy. Allogeneic stem cell therapy is used to treat patients who do not respond fully to treatment, who have high risk of relapse, and relapse after prior successful treatment. Autologous stem cell therapy is a type of therapy that uses the persons own stem cells. These type of cells are collected earlier and returned in future. The use of stem cells is done to replace damaged cells by high doses of chemotherapy, and to treat the persons underlying disease. On the basis of therapeutic applications, the stem cell therapy market is segmented into cardiovascular diseases, wounds and injuries, musculoskeletal disorders, gastrointestinal diseases, surgeries, neurodegenerative disorders, and others. On the basis of cell source, stem cells therapy is segmented into bone marrow-derived mesenchyme stem cells, adipose tissue-derived mesenchyme stem cells, and cord blood or embryonic stem cells

Request For Brochure @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28262

By geography, the market for stem cell therapy is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the stem cell therapy market owing to rising awareness among people, early treatment adoption, and new product innovations. Europe is the second leading market for stem cell therapy due to development and expansion of more efficient and advanced technologies. The Asia Pacific stem cell therapy market is also anticipated to grow at an increasing rate owing to increasing healthcare spending, adoption of western lifestyles, and growth in research and development. Asia Pacific is the fastest growing region for stem cell therapy as several players have invested in the development of new stem cell technologies. These factors are expected to drive the growth of the stem cell therapy market globally during the forecast period.

Request For Custom Research https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=28262

The major player in the stem cell therapy market are Regenexx, Takara Bio Company, Genea Biocells, PromoCell GmbH, CellGenix GmbH, Cellular Engineering Technologies, BIOTIME, INC., Astellas Pharma US, Inc., AlloSource, RTI Surgical, Inc., NuVasive, Inc., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., PHARMICELL Co., Ltd, ANTEROGEN.CO., LTD., The Future of Biotechnology, and Osiris Therapeutics, Inc. Rising demand for advanced stem cell therapies will increase the competition between players in the stem cell therapy market.

Read Our Trending Press Release Below

About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA Canada Toll Free: 866-552-3453 Email:sales@transparencymarketresearch.com Website:https://www.transparencymarketresearch.com/

Read this article:
Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News - FLA News

Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 – The Courier

The report for the worldwideAnimal Stem Cell Therapy marketgives a harsh thought regarding the various factors and patterns influencing the improvement graph of the worldwide market. Advancement of the effect of government strategies and guidelines on the activities in the Animal Stem Cell Therapy market is likewise referenced to offer a comprehensive synopsis of things to come viewpoint of the market. It presents refined development gauges for the Animal Stem Cell Therapy market based on dependable information and contains top to bottom information identified with the predominant elements of the market.

Likewise, the report additionally contains the significant parts in the Animal Stem Cell Therapy market.

Driving Industry Players:ANIMAL CELL THERAPIES, Celavet, Animacel, VETSTEM BIOPHARMA, Cell Therapy Sciences, Magellan Stem Cells, Cells Power Japan, Animal Care Stem, Aratana Therapeutics, VetCell Therapeutics, MediVet Biologic, U.S. Stem Cell, J-ARM

You will discover total data with chapter by chapter list in this leaflet

You can contact our leader staff and get an example duplicate here:http://www.marketresearchstore.com/report/global-animal-stem-cell-therapy-market-report-2020-751651#RequestSample

Whats more in the report alongside significant player details?

The Animal Stem Cell Therapy market report analyzes the market dependent on market sections [Product Types:Dogs, Horses, Others;Product Applications:Veterinary Hospitals, Research Organizations] and significant geologies North America, Europe, Asia Pacific, Latin America, Middle East, Africa, and the rest of the world alongside present patterns on the lookout. The report has information of worldwide market that incorporates an enormous number of rumored associations, sellers, firms, and maker, and can offer a point by point layout of the general players who has a gigantic job as far as income, request, and deals through their solid administrations, post-deal cycles, and items.

Key boundaries that characterize the serious scene of the Global Animal Stem Cell Therapy Market:

The report is a point by point investigation of development drivers, restrictions, and the latest things. It includes itemized profiles of driving business sector players, the examination of late improvements in tech, and interesting model investigation. It offers market projections for the years to come. The report likewise contains an audit of large scale and miniature viewpoints significant for the new participants and current market players alongside the definite examination of the significant worth chain.

The Animal Stem Cell Therapy market report additionally offers a forward-looking perspective on different angles controlling or driving the development of the market. The Animal Stem Cell Therapy market report offers a pin-point examination for changing serious elements. It helps with realizing the significant item areas and their future. It offers a gauge assessed dependent on how the market is guage to create.

Peruse total Report with TOC:http://www.marketresearchstore.com/report/global-animal-stem-cell-therapy-market-report-2020-751651

Whats in store from the Global Animal Stem Cell Therapy Market report:

Centered Study on Strategy, Development and Perception Scenario

Global Top 10 Companies Share Analysis in Animal Stem Cell Therapy Market

Achieve vital experiences on contender data to grow ground-breaking R&D moves

Identify arising players and make viable counter-systems to cross the serious edge

Identify vital and different item types/administrations offering gave by significant players to Animal Stem Cell Therapy market development

Note:To give a more exact market figure, every one of our reports will be refreshed before conveyance considering the impacts of COVID-19.

About Us:

MarketResearchStore.comis a single destination for all the industry, company, and country reports. We feature a large repository of the latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Contact the US:

Joel John Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442 United States Toll Free: +1-855-465-4651 (USA-CANADA) Tel: +1-386-310-3803 Web:http://www.marketresearchstore.com Email:sales@marketresearchstore.com

See the rest here:
Animal Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 - The Courier

Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2025 – The Courier

The report named GlobalStem Cell Therapy Market2020 by Company, Regions, Type, and Application, Forecast to 2025 is a broad audit of the market size and patterns with values. The report is a thorough report on worldwide market investigation and experiences. The report is an arrangement of itemized market outline dependent on sorts, application, patterns and openings, consolidations and acquisitions, drivers and restrictions, and a world coming to. The report centers around the arising patterns in the worldwide and provincial spaces on all the huge segments, for example, market limit, cost, value, request and supply, creation, benefit, and serious scene. It offers a board translation of the worldwide Stem Cell Therapy industry from a scope of data that is gathered through respectable and checked sources.

NOTE:Our experts observing the circumstance across the globe clarifies that the market will create gainful possibilities for makers post COVID-19 emergency. The report means to give an extra outline of the most recent situation, financial stoppage, and COVID-19 effect on the general business.

Market Rundown:

The report investigates past patterns and future possibilities in this report which makes it exceptionally conceivable for the examination of the market. The report gives subtleties of the market by definitions, applications, market plot, item conclusions, and cost structures. The examination moreover shows the market contention scene and a relating point by point examination of the huge dealer/makers in the worldwide Stem Cell Therapy market. At that point, it presents another endeavor SWOT examination, adventure likelihood, and assessment. The report offers a figure assessment of the valuation of the market 2020-2025.

DOWNLOAD FREE SAMPLE REPORT:http://www.marketresearchstore.com/report/global-stem-cell-therapy-market-report-2020-industry-752969#RequestSample

The report talks about an entire attitude toward the difficulties existing among the business alongside the rising dangers, imperatives, and constraints. The report contains a full breakdown of the market elements like drivers, development possibilities, item portfolio, mechanical progressions, and a full investigation of the critical contenders of the market. The overall Stem Cell Therapy market is segmental into types, applications, innovation, end-clients, business verticals, and key geologies.

The central participants concentrated in the report include:Anterogen, Caladrius, RTI Surgical, BIOTIME, Osiris Therapeutics, Pharmicell, AlloSource, MEDIPOST, JCR Pharmaceuticals, BrainStorm Cell Therapeutics, Holostem Terapie Avanzate, Advanced Cell Technology, NuVasive

The main sorts of worldwide market items shrouded in this report are:Autologous, Allogeneic

The most generally utilized downstream fields of the worldwide market canvassed in this report are:Musculoskeletal disorders, Wounds and injuries, Cardiovascular diseases, Surgeries, Gastrointestinal diseases, Other applications

Key areas and nations are canvassed in the worldwide Stem Cell Therapy market as follows: North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, and so forth), Middle East and Africa (Saudi Arabia, Egypt, Nigeria, and South Africa)

The report comprises of a summed up market study and in general insights about the business occasions to key partners to grow their business and catch incomes. The worldwide Stem Cell Therapy market report offers definite examination upheld by solid insights on special and income by players for the time frame 2015-2020. Different subtleties included are organization depiction, significant business, item presentation, ongoing turns of events, deals by area, type, application, and by deals channel.

ACCESS FULL REPORT:http://www.marketresearchstore.com/report/global-stem-cell-therapy-market-report-2020-industry-752969

Advance Information On The Market:

About Us:

MarketResearchStore.comis a single destination for all the industry, company, and country reports. We feature a large repository of the latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Contact the US:

Joel John Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442 United States Toll Free: +1-855-465-4651 (USA-CANADA) Tel: +1-386-310-3803 Web:http://www.marketresearchstore.com Email:sales@marketresearchstore.com

Here is the original post:
Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2025 - The Courier

Pericardial Injection Effective, Less Invasive Way to Get Regenerative Therapies to Heart – NC State News

Injecting hydrogels containing stem cell or exosome therapeutics directly into the pericardial cavity could be a less invasive, less costly, and more effective means of treating cardiac injury, according to new research from North Carolina State University and the University of North Carolina at Chapel Hill.

Stem cell therapy holds promise as a way to treat cardiac injury, but delivering the therapy directly to the site of the injury and keeping it in place long enough to be effective are ongoing challenges. Even cardiac patches, which can be positioned directly over the site of the injury, have drawbacks in that they require invasive surgical methods for placement.

We wanted a less invasive way to get therapeutics to the injury site, says Ke Cheng, Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine at NCStates Department of Molecular Biomedical Sciences and professor in the NCState/UNC-Chapel Hill Joint Department of Biomedical Engineering. Using the pericardial cavity as a natural mold could allow us to create cardiac patches at the site of injury from hydrogels containing therapeutics.

In a proof-of-concept study, Cheng and colleagues from NCState and UNC-Chapel Hill looked at two different types of hydrogels one naturally derived and one synthetic and two different stem cell-derived therapeutics in mouse and rat models of heart attack. The therapeutics were delivered via intrapericardial (iPC) injection.

Via fluorescent imaging the researchers were able to see that the hydrogel spread out to form a cardiac patch in the pericardial cavity. They also confirmed that the stem cell or exosome therapeutics can be released into the myocardium, leading to reduced cell death and improved cardiac function compared to animals in the group who received only the hydrogel without therapeutics.

The team then turned to a pig model to test the procedures safety and feasibility. They delivered the iPC injections using a minimally invasive procedure that required only two small incisions, then monitored the pigs for adverse effects. They found no breathing complications, pericardial inflammation, or changes in blood chemistry up to three days post-procedure.

Our hope is that this method of drug delivery to the heart will result in less invasive, less costly procedures with higher therapeutic efficacy, Cheng says. Our early results are promising the method is safe and generates a higher retention rate of therapeutics than those currently in use. Next we will perform additional preclinical studies in large animals to further test the safety and efficacy of this therapy, before we can start a clinical trial.

I anticipate in a clinical setting in the future, iPC injection could be performed with pericardial access similar to the LARIAT procedure. In that regard, only one small incision under local anesthesia is needed on the patients chest wall, says Dr. Joe Rossi, associate professor in the division of cardiology at UNC-Chapel Hill and co-author of the paper.

The research appears in Nature Communications and was supported by the National Institutes of Health and the American Heart Association. Dr. Thomas Caranasos, director of adult cardiac surgery at UNC-Chapel Hill, also contributed to the work.

-peake-

Note to editors: An abstract follows.

Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair

DOI: 10.1038/s41467-021-21682-7

Authors: Dashuai Zhu, Zhenhua Li, Ke Cheng, North Carolina State University; Thomas Caranasos, Joseph Rossi, University of North Carolina at Chapel Hill Published: March 3, 2021 in Nature Communications

Abstract: Cardiac patch is an effective way to deliver therapeutics to the heart. However, such procedures are normally invasive and difficult to perform. Here, we developed and tested a method to utilize the pericardial cavity as a natural mold for in situ cardiac patch formation after intrapericardial (iPC) injection of therapeutics in biocompatible hydrogels. In rodent models of myocardial infarction (MI), we demonstrated that iPC injection is an effective and safe method to deliver hydrogels containing induced pluripotent stem cells-derived cardiac progenitor cells (iPS-CPCs) or mesenchymal stem cells (MSCs)-derived exosomes. After injection, the hydrogels formed cardiac patch-like structure in the pericardial cavity, mitigating immune response and increasing the cardiac retention of the therapeutics. With robust cardiovascular regeneration and stimulation of epicardium-derived repair, the therapies mitigated cardiac remodeling and improved cardiac functions post MI. Furthermore, we demonstrated the feasibility of minimally-invasive iPC injection in a clinically-relevant porcine model as well as in human patients. Collectively, our study establishes iPC injection as a safe and effective method to deliver therapeutics to the heart for cardiac repair.

See original here:
Pericardial Injection Effective, Less Invasive Way to Get Regenerative Therapies to Heart - NC State News

Glial Cell Discovery Could Point the Way to Motor Neuron Disease Therapies – Technology Networks

Read Time:

Scientists at the Francis Crick Institute and UCL have identified the trigger of a key cellular change in amyotrophic lateral sclerosis (ALS), a type of motor neuron disease. The findings could help develop new treatments for many neurological diseases with the same change, including Parkinson's and Alzheimer's.

When the nervous system is injured, diseased or infected, star-shaped cells, called astrocytes, undergo 'reactive' changes in their behaviour. Whilst some of these reactive astrocytes become protective, others become harmful and damage surrounding motor neurons.

Reactive astrocytes are observed in various neurodegenerative diseases including ALS, but there is a lack of understanding about what causes astrocytes to undergo this change.

In their research, published inNucleic Acids Researchtoday (4th March), the scientists compared ALS-diseased astrocytes with healthy astrocytes to uncover how the diseased cells become reactive. These cells were grown from human induced pluripotent stem cells - master stem cells - which can be directed to differentiate into any cell in the human body.

They found that key to the astrocyte change in diseased cells is an increase in the removal of introns (non-coding sections of genetic information) from RNA in a process called splicing. The team identified that in healthy astrocytes there are some RNAs that normally retain certain introns however in diseased cells these particular introns are spliced out.

This has dramatic consequences on the cell's actions as when these introns are cut out of RNA, the remaining exons (coding sections of genetic information) are used as a recipe for building proteins and some of these proteins play a role in the astrocytes changing.

Rickie Patani, senior author, group leader at the Crick, Professor at UCL's Queen Square Institute of Neurology and a consultant neurologist at the National Hospital for Neurology and Neurosurgery, says: "Understanding how astrocytes undergo this transformation is a really exciting step forward. It brings us closer to potentially being able to control and prevent astrocytes from becoming harmfully reactive. While there's still a long way to go, we're hopeful that developing such a treatment is possible and that it could even potentially be used across all neurological conditions in which an increase in reactive astrocytes is also documented, including Parkinson's and Alzheimer's."

ALS is a rapidly progressing degenerative disease. Patients commonly suffer loss of movement, speech and eventually the ability to breathe, and most people only live 3 to 5 years after diagnosis. There are currently no treatments that can meaningfully alter the prognosis.

But understanding key cellular changes associated with ALS could help develop new therapies to slow disease progression.

Oliver Ziff, lead author and clinical fellow at the Crick, UCL's Queen Square Institute of Neurology and a neurology registrar at the National Hospital for Neurology and Neurosurgery, says: "Our group have previously shown that splicing is decreased in ALS motor neurons, so when we found the opposite in ALS astrocytes we were intrigued. In fact, increased splicing is what we find in other immune cells when they become activated or angry. This raises the possibility that ALS astrocytes inflict a toxic immune insult on the nervous system and opens new therapeutic avenues for treating ALS."

The researchers will continue this work to further understand the molecular mechanisms involved when astrocytes become reactive with the ambition of developing an intervention that could be used by doctors to slow disease progression.

Reference: Ziff OJ, Taha DM, Crerar H, et al. Reactive astrocytes in ALS display diminished intron retention. Nucleic Acids Research. 2021;(gkab115). doi:10.1093/nar/gkab115

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to see the original:
Glial Cell Discovery Could Point the Way to Motor Neuron Disease Therapies - Technology Networks

Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging – OncLive

Biologic aging is a complex process. There are several theories on why and how we age, and it is probable that none of them account for all the aspects. We are constantly exposed to both internal and external stimuli that, over time, facilitate the aging process. These stimuli include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction. These factors accelerate cellular senescencewhat is thought to be the critical factor in aging and has been shown to increase with age.1,2

Cellular senescence is a condition in which a cell has lost the ability to proliferate, and senescent cells increase in almost all organs and tissues as we age. Over time, these changes ultimately lead to the development of significant comorbidities and the cumulative functional deficits we acquire during aging. However, senescent cells are metabolically active and can produce cytokines and inflammatory proteinsthe senescence-associated secretory phenotypefurther accelerating aging and promoting malignancy. FIGURE 1 illustrates the effect of age and insults on senescence.

Accumulation of senescent cells is implicated as a cause of tissue reprogramming, osteoporosis, glaucoma, neurodegeneration, type 2 diabetes, changes in the microbiome, immune system dysfunction, dysfunctional tissue repair and fibrosis, and cancer.3 Recent data have shown the potential role of chemotherapy and radiation therapy in accelerating aging. Nowhere is chemotherapys effect in accelerating aging more apparent than in children and adolescents treated successfully for childhood malignancy.4 In these patients, by the time they reach aged 35 years, approximately 30% have the clinical phenotype of a person aged 65 years, as evidenced by dramatic increases in cardiac disease and new second malignancies.

At the University of North Carolina Lineberger Comprehensive Cancer Center, we have focused on the effects of chemotherapy and accelerated aging in cancer. To date, we have studied the effects of chemotherapy on childhood cancer, early breast cancer, and bone marrow transplantation. Our research has explored the role of p16INK4a expression, a robust marker of biologic aging, following on the work of Norman E. Ned Sharpless, MD, director of the National Cancer Institute. p16INK4a encodes for a protein that blocks cyclin-dependent kinase, analogous to the cyclin-dependent kinase inhibitors now used in breast cancer, including palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio), that prevent cells from entering the cell cycle.5 This leads to cellular senescence. In murine models, aging is associated with dramatic changes in p16INK4a expression in almost all organs over the animals lifespan.6 In human studies, p16INK4a expression is measured in T lymphocytes using a reverse transcription-polymerase chain reaction as a surrogate for aging in other tissues. Studies of p16INK4a expression using other immunohistochemistry methods suggest changes in T cells represent mirror changes in other tissue, and further research in this area is underway.

The change in p16INK4a with aging is not linear, and after 60 years, it appears to plateau for unclear reasons.7 It is possible that those older persons who would have had high levels of p16INK4a expression have already died of age-related illness such as cardiovascular disease, and current studies are addressing this issue.

The large dynamic range of p16INK4a expressionapproximately 10-fold over the human lifespanmakes it an ideal biomarker for study. In healthy children and adolescents, p16INK4a expression is low to undetectable, with high levels appearing in older persons. FIGURE 2 shows the effect of age on p16INK4a expression in 594 patients. These data give p16INK4a expression the potential to be an accurate predictor of cell senescence in an individual patient.

For example, if one hypothesizes that senescent cells are less likely to replicate to ameliorate the adverse effects of chemotherapy (ie, myelosuppression or mucositis), then investigators might be able to accurately predict between 2 patients of the same ageone with high p16INK4a expression and one with lowthat the patient with higher expression would have less cellular reserve and be more vulnerable to adverse effects. Studies are underway to determine if p16INK4a expression measured before treatment will prove to be a predictive marker of toxicity for currently used adjuvant chemotherapy regimens.

Investigators have examined several hundred patients with early breast cancer and a smaller number with childhood cancer and after bone marrow transplantation, and they have found that most chemotherapy regimens cause rapid and sustained increases in p16INK4a expression. Changes are seen shortly and dramatically after beginning chemotherapy, persist over time, and are irreversible.5,8,9 In adolescents and young adults treated with chemotherapy, significant increases in p16INK4a expression were associated with frailty and represented a 35-year acceleration in age among frail young adult cancer survivors. These data mimic what has been clinically noted in large study of adults who had childhood cancer: Approximately one-third of young adults and childhood cancer survivors aged 35 years have a disease phenotype of a person aged 65 years.4 Our group has also found that p16INK4a expression rose markedly in patients treated with allogeneic or autologous stem cell transplants for hematologic malignancies. These patients had a 2- to 3-fold increase in p16INK4a expression corresponding to 16 to 28 years of accelerated aging.10

We have noted similar findings in women with early-stage breast cancer. In patients treated with adjuvant or neoadjuvant chemotherapy, especially with anthracycline-based regimens (doxorubicin, cyclophosphamide, and taxanes with or without carboplatin), p16INK4a expression rose dramatically during chemotherapy and persisted during follow-up. On average, chemotherapy accelerated aging by approximately 17 years of life span, with acceleration of 23 to 27 years for those treated with anthracycline-based treatment.

Of note, docetaxel/cyclophosphamide regimens were associated with only 11 years of aging, and we found no evidence that anti-HER2 therapy affected p16INK4a expression. In these studies, accelerated aging due to chemotherapy represents estimates based on the trajectory of p16INK4a expression in normal patients over their lifespan. We are uncertain of the long-term implications of these changes. In our breast cancer studies, baseline p16INK4a expression was also associated with fatigue. In a recent unpublished analysis (Mitin N, et al), the difference between a patients baseline p16INK4a expression and a normal value for a patient of the same agethe p16 gapwas highly predictive of chemotherapy-induced peripheral neuropathy with taxane chemotherapy. We also found that baseline p16INK4a expression is a significant predictor of a p16 change, independent of age or chemotherapy type, with those patients having lower baseline p16INK4a expression being more likely to have greater changes with any chemotherapy regimen. The reasons for this are unclear, but patients of similar age with higher p16INK4a less ability to overcome tissue and organ damage. Not all chemotherapeutic agentsfor example, taxanes used as a single agentmay be associated with accelerated aging.11 More detailed studies of patients treated with different agents, including immunotherapeutic and other biologic therapies, and for different types of cancer are needed.

The long-term implications of changes in p16INK4a expression with chemotherapy are unknown, but our data suggest that higher levels may be indicators of frailty, a syndrome associate with increased comorbidity, poor quality of life, and shortened survival. p16INK4a expression has been associated with other diseases of aging, including cardiovascular disease, osteoporosis, and other common illnesses, and our chemotherapy-treated patients with accelerated aging may experience major problems 10 to 20 years after treatment, similar to young adults with cancer, and at a time when they are not likely to be followed by their oncologists.

However, these concerns should not mitigate the use of what has proven to be markedly effective treatment regimens that have dramatically improved overall survival in childhood cancer and breast cancer. It is too early to speculate, especially in breast cancer, whether nonanthracycline regimens with similar effectiveness to anthracyclines may be worth considering for patients with long life expectancy. The use of biomarkers in aging research, geroscience, is an exciting area of exploration, and p16INK4a expression is just one of the markers currently being studied.12 The implications of accelerated aging are being studied in other scenarios, and a broad range of studies are exploring interventions to ameliorate biological changes suggesting accelerated aging.

An excellent review of these issues and potential interventions is available13 and describes studies of exercise, diet and nutrition strategies, and senolytics. Learning about the effects of cancer treatment on aging is of major importance, as the clinical scenario of cancer is dominated by older adults who already may have a substantial comorbid illness at the time of diagnosis that might be accelerated by treatment. In children and young adults with cancer, learning how to assess and, in the future, intervene to prevent treatment-related accelerated aging is also a major need.

Read more:
Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging - OncLive

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine…

PHOENIX, March 4, 2021 /PRNewswire/ --(OTC - CELZ)Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease. Evaluation of patients at 30,60 90, 180, and 360 days revealed significant improvement in mobility and reduction in pain score . The mean pain changed from 8.9 at baseline to 4.3 at 30 days and sustained to 1.8 at 6 months and 1.3 at 12 months with a gradual reduction in overall pain medication utilization guided by their healthcare team. No serious adverse effects were noted with some short-term bruising in two patients at the harvest site and no long term adverse events where reported related to the procedure.

"This publication, which is "pre-peer review" describes what to our knowledge is the first demonstration of a signal of clinical efficacy by injecting stem cells in areas surrounding the disc." Said Dr Amit Patel, Board Member and Co-Founder of the Company. "While others have intra-disc injection may help disc pain, the current work regenerates the blood supple to the disc, allowing the disc to heal itself."

The autologous utilization of bone marrow falls under the "minimal manipulation exception" and can be commercialized rapidly, in the same manner that the Company commercialized Caverstem for treatment of erectile dysfunction.

Granted United States Patent #9,598,673 which is owned by the Company covers the use of any mesenchymal stem cells, both from the patient or from donors, for reduction of lower back pain when injected into the major muscles of the lower back.

"Disc degenerative disease represents a multi-billion dollar market for which current medical solutions do not address the underlying cause, while surgery is expensive and not applicable for a significant number of patients." Said Timothy Warbington, President and CEO of the Company. "We are excited to follow the path we did with CaverStem and initiate commercialization of this technology for American patients."

To view our Publication: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3797402

About Creative Medical Technology HoldingsCreative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking StatementsOTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

http://www.StemSpine.com http://www.CaverStem.com http://www.FemCelz.com

SOURCE Creative Medical Technology Holdings, Inc.

Home

Continue reading here:
Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine...